Elisabetta Schiavello
Boston Children's Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Elisabetta Schiavello.
Journal of Clinical Oncology | 2010
Andrea Ferrari; Rosalba Miceli; Cristina Meazza; Michela Casanova; Francesca Favini; Carlo Morosi; Giovanna Trecate; Alfonso Marchianò; Roberto Luksch; Graziella Cefalo; Monica Terenziani; Filippo Spreafico; Daniela Polastri; Marta Podda; Serena Catania; Elisabetta Schiavello; Patrizia Giannatempo; Lorenza Gandola; Maura Massimino; Luigi Mariani
PURPOSE In this study on a series of 205 patients with rhabdomyosarcoma, we investigated whether the prognostic effect of tumor size, at diagnosis or in terms of tumor response after induction chemotherapy, differed when tumor diameter or tumor volume were considered. PATIENTS AND METHODS Tumor size was assessed radiologically at diagnosis and, for the 108 patients with measurable disease, after three courses of chemotherapy. The analysis was based on multivariable models (linear for association between size and patient/tumor characteristics, Cox for association with survival). The predictive performance of the Cox model (estimated by V measure) was compared for the tumors diameter and volume. RESULTS Initial tumor size was significantly larger in male or older patients and in T2 or alveolar tumors, but was not associated with the achievement of complete surgical resection. Initial tumor size significantly influenced overall survival. The risk of death was comparable for tumors 10 cm in maximum diameter and 194.0 cm(3) in volume. The predictive performance of the Cox model was much the same when the tumors diameter or volume was considered. Tumor response was a significant predictor of survival, again irrespective of the type of tumor measurement considered. CONCLUSION In our analysis, initial tumor size and tumor response were significant prognostic factors in rhabdomyosarcoma, regardless of whether tumor diameter or volume was considered. Three-dimensional tumor assessment was of no greater prognostic value than one-dimensional assessment, neither initially nor after induction treatment.
Journal of Clinical Oncology | 2015
Andrea Ferrari; Laura Veneroni; Carlo Alfredo Clerici; Michela Casanova; Stefano Chiaravalli; Chiara Magni; Roberto Luksch; Monica Terenziani; Filippo Spreafico; Daniela Polastri; Cristina Meazza; Serena Catania; Elisabetta Schiavello; Veronica Biassoni; Marta Podda; Luca Bergamaschi; Nadia Puma; Carla Moscheo; Giacomo Gotti; Maura Massimino
Andrea Ferrari, Michela Casanova, Stefano Chiaravalli, Chiara Magni, Roberto Luksch, Monica Terenziani, Filippo Spreafico, Daniela Polastri, Cristina Meazza, Serena Catania, Elisabetta Schiavello, Veronica Biassoni, Marta Podda, Luca Bergamaschi, Nadia Puma, Carla Moscheo, Giacomo Gotti, Maura Massimino, Fondazione IRCCS Istituto Nazionale Tumori; Laura Veneroni, Carlo Alfredo Clerici, University of Milan, Milan, Italy.
Tumori | 2012
Andrea Ferrari; Carlo Alfredo Clerici; Michela Casanova; Roberto Luksch; Monica Terenziani; Filippo Spreafico; Daniela Polastri; Cristina Meazza; Laura Veneroni; Serena Catania; Elisabetta Schiavello; Veronica Biassoni; Marta Podda; Maura Massimino
The paper describes the key issues of the Youth Project launched in 2011 at the pediatric oncology unit of the Istituto Nazionale Tumori in Milan dedicated to adolescents (over 15 years old) and young adults (up to 25 years old) with solid tumors. The Youth Project was developed within the pediatric oncology unit in the conviction that adolescent patients may benefit from the multidisciplinary team typical of the pediatric oncology setting, as well as the expertise in treating pediatric-type malignancies and enrolling patients in clinical trials. The project was an offshoot of existing activities, making no major changes to the hospitals organization and posing no major demands on the institutions administration and board. Patients are managed by the pediatric oncology staff, but they have access to particular services (e.g., regarding their psychosocial support, fertility preserving measures, access to care after completing therapy); dedicated, adequately equipped multifunctional rooms have been provided. The location of the pediatric unit within a cancer referral center and the cooperation with divisions dedicated to adults have played an important role in the projects creation.
Pediatric Blood & Cancer | 2013
Maura Massimino; Manila Antonelli; Lorenza Gandola; Rosalba Miceli; Bianca Pollo; Veronica Biassoni; Elisabetta Schiavello; Francesca R. Buttarelli; Filippo Spreafico; Paola Collini; Felice Giangaspero
Medulloblastoma histological classification has gained in importance and newer treatment protocols will include histology stratification. We centrally reviewed medulloblastoma cases from past 10 years reassessing their histology to ascertain its prognostic significance.
Neuro-oncology | 2016
Maura Massimino; Rosalba Miceli; Felice Giangaspero; Luna Boschetti; Piergiorgio Modena; Manila Antonelli; Paolo Ferroli; Daniele Bertin; Emilia Pecori; Laura Valentini; Veronica Biassoni; Maria Luisa Garrè; Elisabetta Schiavello; Iacopo Sardi; Armando Cama; Elisabetta Viscardi; Giovanni Scarzello; Silvia Scoccianti; Maurizio Mascarin; Lucia Quaglietta; Giuseppe Cinalli; B. Diletto; Lorenzo Genitori; Paola Peretta; Anna Mussano; Annamaria Buccoliero; Giuseppina Calareso; Salvina Barra; Angela Mastronuzzi; Carlo Giussani
BACKGROUND This prospective study stratified patients by surgical resection (complete = NED vs incomplete = ED) and centrally reviewed histology (World Health Organization [WHO] grade II vs III). METHODS WHO grade II/NED patients received focal radiotherapy (RT) up to 59.4 Gy with 1.8 Gy/day. Grade III/NED received 4 courses of VEC (vincristine, etoposide, cyclophosphamide) after RT. ED patients received 1-4 VEC courses, second-look surgery, and 59.4 Gy followed by an 8-Gy boost in 2 fractions on still measurable residue. NED children aged 1-3 years with grade II tumors could receive 6 VEC courses alone. RESULTS From January 2002 to December 2014, one hundred sixty consecutive children entered the protocol (median age, 4.9 y; males, 100). Follow-up was a median of 67 months. An infratentorial origin was identified in 110 cases. After surgery, 110 patients were NED, and 84 had grade III disease. Multiple resections were performed in 46/160 children (28.8%). A boost was given to 24/40 ED patients achieving progression-free survival (PFS) and overall survival (OS) rates of 58.1% and 68.7%, respectively, in this poor prognosis subgroup. For the whole series, 5-year PFS and OS rates were 65.4% and 81.1%, with no toxic deaths. On multivariable analysis, NED status and grade II were favorable for OS, and for PFS grade II remained favorable. CONCLUSIONS In a multicenter collaboration, this trial accrued the highest number of patients published so far, and results are comparable to the best single-institution series. The RT boost, when feasible, seemed effective in improving prognosis. Even after multiple procedures, complete resection confirmed its prognostic strength, along with tumor grade. Biological parameters emerging in this series will be the object of future correlatives and reports.
Pediatric Blood & Cancer | 2016
Andrea Ferrari; Salvatore Lo Vullo; Daniele Giardiello; Laura Veneroni; Chiara Magni; Carlo Alfredo Clerici; Stefano Chiaravalli; Michela Casanova; Roberto Luksch; Monica Terenziani; Filippo Spreafico; Cristina Meazza; Serena Catania; Elisabetta Schiavello; Veronica Biassoni; Marta Podda; Luca Bergamaschi; Nadia Puma; Maura Massimino; Luigi Mariani
The potential impact of diagnostic delays on patients’ outcomes is a debated issue in pediatric oncology and discordant results have been published so far. We attempted to tackle this issue by analyzing a prospective series of 351 consecutive children and adolescents with solid malignancies using innovative statistical tools.
Pediatric Blood & Cancer | 2016
Andrea Ferrari; Matteo Silva; Laura Veneroni; Chiara Magni; Carlo Alfredo Clerici; Cristina Meazza; Monica Terenziani; Filippo Spreafico; Stefano Chiaravalli; Michela Casanova; Roberto Luksch; Serena Catania; Elisabetta Schiavello; Veronica Biassoni; Marta Podda; Luca Bergamaschi; Nadia Puma; Alice Indini; Tullio Proserpio; Maura Massimino
Various projects dedicated specifically to adolescents and young adults (AYA) with cancer have been developed in recent years. A critical aspect of such programs is the ability to demonstrate its value, and therefore how to measure desired outcomes.
Journal of Pediatric Hematology Oncology | 2012
Julián Sevilla; Elisabetta Schiavello; Luis Madero; Manuela Pardeo; Elena Guggiari; Marta Baragaño; Roberto Luksch; Maura Massimino
Plerixafor has been recently approved by the European Medicines Agency for adult patients who have failed other mobilization strategies. Experience in children, however, is extremely limited. We describe the experience of the use of this drug in 8 children under a compassionate-use program in 3 Italian and 2 Spanish centers. Plerixafor was generally well tolerated; only 2 of 8 children reported adverse effects, and these were mild in intensity. Peripheral blood progenitor cell priming was improved with plerixafor in 6 of 8 patients. In the remaining 2 patients, the target CD34+ cell count was below the target of 2×106 cells/kg, although in these patients cell counts before collection were good enough for leukapheresis. Plerixafor, therefore seems to be safe and effective for peripheral blood progenitor cell mobilization in children. Adverse events were comparable with those described with filgrastim alone.
Pediatric Blood & Cancer | 2013
Maura Massimino; Lorenza Gandola; Veronica Biassoni; Filippo Spreafico; Elisabetta Schiavello; Geraldina Poggi; Emilia Pecori; Marco Vajna De Pava; Piergiorgio Modena; Manila Antonelli; Felice Giangaspero
A protocol for the intensive treatment of non‐cerebellar PNET (CNS‐PNET) combining chemotherapy and radiotherapy was launched in 2000. Efforts were subsequently made to improve the prognosis and to de‐escalate the treatment for selected patient groups.
Tumori | 2010
Marta Giorgia Podda; Roberto Luksch; Daniela Polastri; Lorenza Gandola; Luigi Piva; Paola Collini; Graziella Cefalo; Monica Terenziani; Andrea Ferrari; Michela Casanova; Filippo Spreafico; Cristina Meazza; Maria Rita Castellani; Serena Catania; Elisabetta Schiavello; Alfonso Marchianò; Maura Massimino
AIMS AND BACKGROUND Neuroblastoma is the most common solid extracranial tumor in children. The median age of onset is 2 years, with more than 95% of patients younger than 10 years at diagnosis. As neuroblastoma is rare in adolescents and exceedingly rare in adults, few series are reported in the literature. In the present study, we analyzed the outcomes and clinical characteristics of a mono-institutional series. METHODS We describe 27 consecutive patients over 12 years of age (range, 12-69) with previously untreated neuroblastoma treated at our Institution between 1982 and 2001. RESULTS Overall survival at 5 and 10 years was 40% and 20%, respectively, and progression-free survival at 5 and 10 years was 18%. In the present series, there was a long interval between the onset of signs/symptoms and diagnosis, and between recurrence/progression and death. None had MYCN amplification. CONCLUSIONS The passive course of the disease in most of our patients did not reflect a more favorable outcome compared with younger patients, thus suggesting a possible genetically different subset of neuroblastoma in older patients.